CYP19A1 and breast carcinoma: In agreement with our data, clinical reports have shown that concomitant treatment with HDAC inhibitors and aromatase inhibitors (AIs) significantly improves progression-free survival in hormone receptor–positive advanced breast cancer patients who have progressed on previous endocrine therapies [26].